Accordingly, we sought to expand on previous modeling to determine disease prevalence, treatment distribution, and survival outcomes for patients with severe AS aged ≥60 years. Using a mixed methodology of meta-analysis and stochastic simulation, our analysis estimates the number of patients with severe AS eligible for AVR across 37 countries comprising the International Monetary Fund's 2015 advanced economies index. Key Words: aortic valve ◼ aortic valve stenosis ◼ heart valve prosthesis ◼ transcatheter aortic valve replacement ◼ meta-analysis
S
ince the release of the first The Placement of Aortic Transcatheter Valve Trial (PARTNER) trial, transcatheter aortic valve replacement (TAVR) has been widely accepted as the preferred approach for selected high-risk/inoperable patients with severe symptomatic aortic stenosis (AS). 1, 2 In 2013, Osnabrugge et al 3 modeled the number of high-risk patients eligible for TAVR in the general population aged ≥75 years. The authors identified ≈290 000 candidates across 21 countries in Europe and North America. Since this report, the total number of TAVR procedures has grown to >200 000 across >1000 centers in 50 countries. 4 Although surgical aortic valve replacement (SAVR) remains the primary modality for valve replacement in patients with severe AS, 5 the use of TAVR in lower-risk patients is increasing as clinical practice anticipates the results of ongoing trials. Most recently, Edwards Lifesciences received expanded indication approvals from the US Food and Drug Administration for the SAPIEN 3 and SAPIEN XT in intermediate-risk patients. Unfortunately, there are limited data detailing the distribution of lower-risk patients eligible for TAVR (or SAVR). Indeed, quantification of disease prevalence and treatment eligibility will facilitate data-driven decision making with respect to resource allocation, operator training, and financial reimbursement.
Methods
Four systematic searches were conducted across MEDLINE, EMBASE, and the Cochrane database for studies evaluating disease prevalence, severity, decision making, and outcomes in patients with AS. Search terms (and combinations thereof) included aortic stenosis, valvular heart disease, prevalence, epidemiology, severe, symptomatic, surgical aortic valve or SAVR, and transcatheter aortic valve or TAVR. Search results were limited to studies published in English during the 20-year period from January 1996 to December 2015. Citations were screened using the title and abstract, with the full article retrieved if it reported ≥1 of disease prevalence in the general population, distribution of AS by severity with or without symptom status, SAVR or TAVR eligibility, risk profile in patients undergoing SAVR, and postoperative mortality. Additional articles were identified from reference lists where appropriate. Studies were reviewed by 2 independent investigators at each stage, with data extraction including study characteristics (ie, author, year, journal, study design, enrollment period, inclusion criteria, and AS definition), methodological quality and outcomes, as per the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement. Study quality was assessed using the Quality Index Assessment Criteria for Methodology of Studies, adopting a threshold of 12 for study inclusion. 6 Disagreements relating to study inclusion were solved by consultation with a third investigator. Only original peer-reviewed publications enrolling patients from advanced economies were included in the analysis.
Studies evaluating disease prevalence were included if they met the following criteria: (1) random sampling in a representative population, (2) diagnosis using objective echocardiographic assessment, and (3) outcomes reported by age category (or in a way that facilitates calculation of prevalence in the population aged ≥60 years). Studies directly or indirectly reporting disease severity were included if (1) enrollment of patients was either random or consecutive and (2) AS severity was determined by echocardiographic assessment. Studies directly or indirectly reporting AVR eligibility were included if (1) enrolled patients had a priori defined severe AS, (2) symptom status was reported (with symptomatic AS defined by a clinical history of angina, syncope, and congestive heart failure), and (3) intervention rate was reported for AVR as number of patients. Data pertaining to all-cause mortality were extracted from studies comparing outcomes in patients receiving SAVR or medical therapy. Studies reporting the risk profile of patients undergoing isolated SAVR were included if (1) enrollment of patients was consecutive, (2) risk score was prospectively collected, and (3) patient risk was reported by category using a defined European System for Cardiac Operative Risk Evaluation (EuroSCORE) threshold (or interval) or Society of Thoracic Surgery Predicted Risk of Mortality (STS-PROM) score. Studies reporting TAVR eligibility were included if (1) patients were referred for assessment of eligibility, (2) enrollment of patients was consecutive, and (3) enrollment was consistent with regional guidelines at the time of recruitment. The exclusion criteria reported in each individual study was not used to determine inclusion in the meta-analysis.
Studies were excluded if ≥1 of the following criteria applied: duplicate publication; subgroup analysis of a previously reported cohort; publication in the form of an abstract, case report, conference presentation, or editorial; undefined recruitment protocol; and unclear reporting of outcomes such that the relevant statistics could not be extracted or calculated. Where duplicated data were identified, the study with the largest sample was used. With respect to TAVR eligibility, studies performed in the United States before the release of PARTNER I (NCT00530894) findings were excluded because of stricter inclusion criteria which have since eased in line with earlier European trials.
Disease prevalence, represented as rate and 95% confidence interval (95% CI), was determined for each study population by extraction of sample size and patient number by age category. Thereafter, prevalence was evaluated as a pooled estimate using fixed-and randomeffects models, where appropriate. Patient progression to AVR was mapped using pooled estimates of: symptom status in patients with severe AS, risk score (EuroSCORE or STS-PROM), and as-treated intervention rates. Individual patient characteristics were not obtained. Estimates of disease prevalence and treatment eligibility were calculated using Monte Carlo methods (n=100 000) with probability distributions parametrized using the aforementioned pooled statistics. Population estimates for 2015, 2016, and 2020 were sourced for the 37 Data analysis was conducted using R Studio (GNU General Public License). Weighted point estimate and risk ratio were calculated for the pooled study population, with results presented as weighted point estimate or risk ratio and 95% CI. Fixed-and random-effects models utilized the inverse variance and DerSimonian and Laird methods, respectively. Statistical heterogeneity, a measure of variability across trials not because of chance, was assessed using the Cochran-Q and I 2 statistics. Moderate heterogeneity was considered to be present for an I 2 >50% and P<0.10. Accordingly, conclusions were based on analysis using the random-effects models. Sensitivity analysis was performed using the 1-study exclusion method. A ≥15% modification of the pooled estimate was considered significant. Publication bias was assessed by inspection of funnel plots for asymmetry and Egger regression test with P<0.10 considered significant.
Results
Of the 4514 studies identified during the systematic search, with an additional 47 found through cross-referencing, 4037 were excluded on initial review owing to inadequate diagnostic criteria, biased patient selection, duplicate data, non-original publication, and an unclear methodology (Figure 1) . After assessment of 524 full articles, 56 studies were included for analysis with 42 965 patients extracted (not
WHAT IS KNOWN
• Aortic stenosis is a significant and increasing burden on the healthcare system. • Since the first procedure in 2002, transcatheter aortic valve replacement has become the standard of care for high-risk patients with severe symptomatic aortic stenosis.
WHAT THE STUDY ADDS
• This study documents the prevalence and progression of severe AS in advanced economies, from diagnosis to intervention. • This study reports regional and national estimates for the number of patients with AS, the number of patients eligible for AVR and the growth of TAVR by risk profile.
• This study identifies the disparity that exists between the number of AVR procedures per year and the number of patients requiring treatment. TAVR in Low-Risk Patients including 141 905 patients used for sensitivity analysis of preoperative risk score).
Characteristics of the studies used to estimate disease prevalence are presented in Table 1 (see Data Supplement for prevalence studies that were excluded because of patient selection and disease classification). Disease prevalence ranged from 1.3% to 7.8% for people aged 60 to 74 years and 2.6% to 22.8% for people aged ≥75 years. The pooled prevalence was 2.8% (95% CI, 1.4%-4.1%) and 13.1% (95% CI, 8.2%-17.9%), respectively ( Figure 2A ). The portion of AS classified as severe was reported in 6 of the 9 populations ranging from 11.5% to 26.7%. The pooled estimate was 19.9% (95% CI, 12.8%-26.9%; Figure 2B ).
Disease progression to SAVR and TAVR (for highrisk/inoperable patients) is reported in Figure 3 Figure 6 ). Of the patients who underwent SAVR, 57.4% (95% CI, 41.3%-73.6%) were classified as low risk based on EuroSCORE assessment (Figure 7) . The characteristics of studies investigating TAVR eligibility are presented in Table 2 . Of the high-risk/inoperable patients referred for TAVR assessment, 56.0% (95% CI, 50.2%-61.8%) were eligible ( Figure 8 ), of whom 84.6% (95% CI, 79.0%-90.2%) received TAVR with 15.4% (95% CI, 9.8%-21.0%) refusing intervention.
The overall prevalence of AS in the study population was 4.5%, corresponding to an estimated 16.1 million (95% CI, 12.2-20.3) people across the 37 advanced economies. Disease prevalence and AVR eligibility for 2015, stratified by country and procedural type, are presented in Tables 3 and  4 . By region, there is an estimated 7.5 million (95% CI, 5.7-9.5) people in Europe, 4.5 million (95% CI, 3. Pooled estimates remained stable on sensitivity analysis for all parameters except prevalence in the general population aged 60 to 74 years. On removal of the Taiwanesebased study by Lin et al, 11 adjusting prevalence to 1.4% (95% CI, 1.2%-1.6%), ≈300 000 fewer patients with severe AS were eligible for SAVR. Despite this, the estimated number of TAVR candidates remained similar at 485 250 (95% CI, 286 170-740 190). In a second analysis, the proportion of SAVR patients classified as high, intermediate, and low risk was adjusted to 6.2%, 13.9%, and 79.9%, respectively-based on a 2015 registry study that used STS-PROM score to classify 141 905 patients who underwent 
CI, 304 310-814 870). No evidence of publication bias was identified on Egger test for measures of prevalence, symptom status, or AVR eligibility.

Discussion
This meta-analysis presents a quantitative analysis of the progression of severe AS, from diagnosis to intervention, extending the current understanding of patient distribution along the path to AVR. Moreover, this study quantifies the breadth of disease burden in advanced economies highlighting the need for expansion in operational capacity and payer reimbursement.
The present study reports a disease prevalence of 2.8% and 13.1% in the general population aged 60 to 74 years and ≥75 years, respectively. Subsequent modeling estimates that 16.1 million people across 37 advanced economies have AS. Of these, 1.9 million patients are eligible for SAVR with 485 230 high-risk/inoperable patients eligible for TAVR. These figures underscore the growing disparity between the number of replacement procedures and clinical need for treatment. SAVR is projected to reach 500 000 cases per year by 2020. 52 Even if the patient demand remained stable, this number is inadequate. Our analysis projects that 17.9 million patients will have AS within 5 years or ≈331 300 new cases per year including 65 600 patients diagnosed with severe AS.
The data used to quantify each step of the analysis (from prevalence to TAVR eligibility) were extracted from studies performed in advanced economies. Accordingly, estimates of disease prevalence and patient eligibility were restricted to the 37 countries comprising the International Monetary Fund's advanced economies index. Inherent in the study design is the assumption that prevalence and intervention rates are generalizable across these countries. In reality, there are likely to be differences from one country to the next. Indeed, favorable reimbursement schemes and local decision making may Distribution of patients along the AVR pathway raises many questions. The literature has consistently demonstrated mortality rates of up to 50% within 3 to 5 years from symptom onset in patients with severe AS. [53] [54] [55] Yet, this study reports that >40% of patients with severe symptomatic AS did not undergo SAVR. Equally surprising, <30% of patients with asymptomatic AS underwent SAVR despite at least a 25% reduction in mortality when compared with medical therapy. It should be noted that 5 of the 6 studies reporting outcomes for asymptomatic AS included patients with low left ventricular ejection fraction. This cohort of asymptomatic patients is known to have poorer outcomes. Accordingly, their inclusion may have disproportionately influenced the observed mortality benefit with SAVR. Likewise, it may also have contributed to the finding that close to half of the asymptomatic patients treated with medical therapy progressed to SAVR within 2 years after symptom onset. Irrespective of symptom status, 20% of patients who received medical therapy did so because they refused surgical intervention. The reasons for treatment refusal were not explored in this study and may include reimbursement. Nevertheless, these data underscore the disparity With respect to TAVR, notwithstanding the rapid rise in adoption since the first procedure in 2002, 56 the present metaanalysis indicates that only 56% of high-risk/inoperable patients referred for TAVR were eligible. This is not entirely unexpected given that TAVR was initially reserved for contraindicated surgical patients. Using data from the German Aortic Valve Registry, Reinöhl et al 57 have shown an overall increase in the number of AVR procedures between 2007 and 2013 with TAVR increasing by 9003 compared with a decrease in SAVR by 1574. The majority of this increase was seen in the cohort aged ≥80 years whereby a small reduction in SAVR was considerably outpaced by the increase in TAVR. This suggests that the 2 modalities are complementary with additional patients being treated beyond those who would have undergone SAVR previously. In contrast, TAVR in younger patients offset the reduction in SAVR, suggesting that TAVR in the lower-risk population will compete with SAVR. Of note, Germany has one of highest rates of TAVR adoption in Europe as a result of their TAVR-specific national diagnosis-related group reimbursement scheme. In 2013, Mylotte et al 58 demonstrated a 3.3-fold increase in the number of TAVR procedures per million population in healthcare systems using TAVR-specific reimbursement schemes. In countries with lower rates of TAVR adoption, it is possible that TAVR has been limited to inoperable patients. Thus, a shift toward lower-risk patients will see TAVR compete directly with SAVR, with an estimated 530 000 patients being eligible for both TAVR and SAVR.
A significant barrier to TAVR adoption is the costs associated with device procurement and implantation. Moreover, the cost-effectiveness compared with SAVR is unclear. Analysis of the US CoreValve High-Risk Trial has demonstrated higher index admission and projected lifetime costs with TAVR when compared with SAVR ($11 260 and $17 849 increase per patient, respectively). 59 In contrast, transfemoral access was associated with lower costs and higher quality-adjusted life-years gained in PARTNER I-with TAVR being dominant over SAVR in 70.9% of bootstrap replicates (incremental costeffectiveness ratio <$50 000/quality-adjusted life-years). 60 Irrespective of treatment modality, the estimated number of patients in need of valve replacement presents a considerable challenge to policy makers. From a fiscal perspective, treating all patients eligible for valve replacement in this study would require a budget of at least $149.9 billion (95% CI lower bound)-calculated using mean 12-month cost from PARTNER I. 38 Aside from the direct financial costs of the procedure, additional treatment centers and operators would be required. Expansion of TAVR to low-risk patients may prompt a reduction in device cost allowing for earlier intervention thus redirecting financial resources to training or infrastructure. Reductions in procedural time, hospital length of stay, and rehabilitation days 38 may allow for a higher throughput of patients-ultimately increasing the number of beds and staff available. However, it should be noted that the long-term durability of TAVR remains unknown with recent reports indicating deterioration within 10 years for the first generation of transcatheter valves. 61 Likewise, it remains unclear as to whether TAVR is, at the least, noninferior to SAVR in the lowrisk cohort. The purpose of the present study was to quantify current treatment patterns and estimate patient eligibility. Any decision to expand TAVR into younger, low-risk patients will require evidence of durability and outcomes comparable to SAVR. In the short-term, SAVR will likely remain the primary modality for valve replacement in this cohort-especially for younger patients and patients with asymptomatic disease.
Study Limitations
With respect to estimating patient numbers, measures of uncertainty were incorporated at each step to calculate intervals representing the likelihood of the final estimates. For TAVR eligibility, estimates may disproportionately represent European experience as risk profile was determined using EuroSCORE. The decision to use EuroSCORE for the primary analysis was based on the greater number of included studies reporting EuroSCORE relative to STS-PROM. The decision to include studies that used hospital-based eligibility criteria and not a specific trial standard (ie, the PARTNER exclusion criteria) was based on the desire to provide findings that represent broader clinical practice.
For estimates of post-operative survival, the concomitant effect of coexisting disease could not be directly assessed. Although risk profile measures like EuroSCORE or STS-PROM score may be used as a surrogate for AVR patients, Figure 8 . Forest plot showing the eligibility of high-risk/inoperable patients referred for transcatheter aortic valve replacement (TAVR), random-effects models (n=1698). [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] CI indicates confidence interval. TAVR in Low-Risk Patients these scores do not capture every characteristic that may affect outcomes. Unfortunately, individual patient data were not provided to enable matching or reporting of sex-based and racial/ ethnic-based differences. In addition, patients receiving medical therapy were not stratified by risk. Accordingly, patients who refused SAVR were included in estimates of SAVR eligibility but not of TAVR eligibility.
However, studies in this analysis used echocardiography to identify AS classification criteria varied. The influence of differing methodologies on estimates of disease prevalence, severity, and symptom status should be considered when interpreting the results of this study. Heterogeneity was explored by comparison of study characteristics, assessment of funnel plot asymmetry, and Egger linear regression method, where appropriate. The repeatedly high I 2 statistic increases the uncertainty of the patient estimates with each successive step in the simulation. Sensitivity analysis was used in the case of prevalence in the general population aged 60 to 74 years. Likewise, a separate analysis was performed substituting EuroSCORE for STS-PROM. The reduction in estimated SAVR candidates with a change in the initial prevalence parameter highlights the limitations of the modeling approach, specifically the dependence on the methodologies of the studies comprising the meta-analysis.
In conclusion, the present study adopted a mixed methodology of meta-analysis and stochastic simulation to quantify the Given the trend toward TAVR in lower-risk patients, together with an aging population, healthcare systems must look at ways to accommodate the increase in patient numbers, operator shortage, and hospitalization of untreated patients with severe AS.
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